title: What constitutes optimal neurohumoral antagonism in chronic heart failure?
authors.affiliation: Stavanger University Hospital, Stavanger, Rogaland, Norway.
authors.forename: Athar Ali
authors.initials: AA
authors.lastname: Tajik
authors.affiliation: University of Bergen, Stavanger University Hospital, Stavanger, Rogaland, Norway.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Dickstein
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D005355:Fibrosis; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D020127:Recovery of Function; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012307:Risk Factors; D013318:Stroke Volume / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000187:drug effects* / Q000503:physiopathology; D016896:Treatment Outcome; D020257:Ventricular Remodeling / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D000451:Mineralocorticoid Receptor Antagonists